The aim of the study was to investigate the efficiency and safety of zoledronic acid and ibandronate in the treatment of rats with lung cancer combined with bone metastases. A total of 124 rats with lung cancer bone metastasis were established. Rats were randomly divided into A, B and C groups (n=30). Rats in group A were treated with ibandronate combined with zoledronic acid, rats in group B were treated with zoledronic acid monotherapy, and rats in group C were treated with ibandronate monotherapy. Rats in group A were injected subcutaneously with zoledronic acid 0.1 mg/kg and ibandronate 10 µg/kg, once per week for 12 weeks; rats in group B were injected subcutaneously with zoledronic acid, and rats in group C were injected subcutaneously with ibandronate, the same method as the treatment group. The remaining 34 SD rats were not treated to serve as the control group. Treatment efficacy and physical improvement in 8 weeks were observed, and improvement of pain behavior in rats was evaluated to reflect the effect of drug treatment. Of the 30 rats in group A, 25 showed different degrees of remission, 5 rats showed no improvement and the effective rate was 83.3%. Of the 30 rats in group B, 21 showed different degrees of remission, 9 rats showed no improvement and the effective rate was 70%. Of the 30 rats in group C, 20 showed different degrees of remission, 10 rats showed no improvement and the effective rate was 66.7%. Statistically significant differences in total effective rate were found among three groups, and the combined method showed the highest effective rate (P<0.05). Ibandronate combined with zoledronic acid has a good therapeutic effect on cancer pain caused by bone metastases from lung cancer.
Background: Osteoarthritis (OA) is a heterogeneous disease caused by the pathology of the synovial joint. About 10-12% of adults have symptomatic OA. In this study, the proteomics method was used to find differentially expressed proteins and to explore the material basis of traditional Chinese medicine (TCM) classification in knee OA patients.Methods: Fifteen patients of the treatment group with knee OA of three different classifications were divided into three groups according to the dialectical classification of TCM: kidney deficiency type (5 cases), Yang deficiency type (5 cases), blood stasis type (5 cases). Also, five patients with traumatic synovitis were enrolled as the control group. The joint fluids were drawn separately. The joint fluids before treatment were Aa, Ba, and Ca groups. After one week of medication, the three joint fluid types were drawn again, and they were Ab group, Bb, and Cb groups. Liquid from the control group was named group D. Quantitative analysis of protein expression was conducted to find out the differently expressed proteins. The treatment group was treated with prescriptions for syndromes according to the TCM classification. Results:The proteomics analysis identified 251 differentially expressed protein groups, and the number of groups with quantitative information for all seven channels was 246. The three treatment groups and the control group had 32 differential proteins (P<0.01), of which nine might be differential proteins between OA and traumatic synovitis. Histone H4, histone H2A, S100 calbindin A8, fibrinogen γ, fiber protein α, cDNA (FLJ92148), C4b binding protein, and partial transketolase variants were down-regulation, and basement membrane glycan was up-regulation in the treatment group compared with the control group (P<0.01).HIST1H2BC and myeloperoxidase levels in the Aa group were less than those in the D and Ab groups.The serum amyloid P and apolipoprotein CI variants in the Ba group were less than those in the D and Bb groups. Histone H2A and C-reactive protein, Fibrinogen α levels in the Ca group were less than those in the D and Cb groups.Conclusions: Nine proteins are closely related to OA of different TCM classification.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.